라임병 진단 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global lyme disease diagnostics market size is expected to reach USD 1.71 Billion in 2034 from USD 1.05 Billion in 2025, growing at a CAGR of 5.57 during 2026-2034.This market is expanding as awareness of tick-borne diseases increases and healthcare systems improve diagnostic capabilities. Lyme disease diagnostics involve tests to detect infection caused by Borrelia bacteria, enabling timely treatment. The rising incidence of Lyme disease in various regions is contributing to market growth.

Growth is supported by advancements in diagnostic technologies, increasing healthcare awareness, and the expansion of laboratory infrastructure. Serological tests and molecular diagnostics are widely used to detect the disease. The growing focus on early detection and preventive healthcare is also driving demand. Additionally, research and development efforts are improving test accuracy and reliability.

Future prospects remain promising, with innovation in rapid and point-of-care diagnostic solutions. The development of more accurate and accessible tests will enhance disease management. Emerging markets are expected to offer growth opportunities due to improving healthcare access. As awareness and diagnosis improve, the Lyme disease diagnostics market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Diagnostic Technology

• Serological Test
• Lymphocytic Transformation Test
• Urine Antigen Testing
• Immunofluorescent Staining

By End User

• Hospitals
• Clinical Laboratories
• Others

COMPANIES PROFILED

• Abbott, Bio-Rad Laboratories Inc., Covance Inc., F. Hoffmann-La Roche AG, T2 Biosystems Inc, Oxford Immunotec USA Inc., LabCorp, Quest Diagnostics, bioMerieux SA, DiaSorin S.p.A, Meridian Bioscience, Inc., Quidel Corporation, Thermo Fisher Scientific Inc., Qiagen

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LYME DISEASE DIAGNOSTICS MARKET: BY DIAGNOSTIC TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Diagnostic Technology
• 4.2. Serological Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lymphocytic Transformation Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Urine Antigen Testing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunofluorescent Staining Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LYME DISEASE DIAGNOSTICS MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clinical Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LYME DISEASE DIAGNOSTICS MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Diagnostic Technology
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Diagnostic Technology
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Diagnostic Technology
  • 6.4.2 By End User
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Diagnostic Technology
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Diagnostic Technology
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL LYME DISEASE DIAGNOSTICS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Abbott
  • 8.2.2 Bio-Rad Laboratories Inc
  • 8.2.3 Covance Inc
  • 8.2.4 F. Hoffmann-La Roche AG
  • 8.2.5 T2 Biosystems Inc
  • 8.2.6 Oxford Immunotec USA Inc
  • 8.2.7 LabCorp
  • 8.2.8 Quest Diagnostics
  • 8.2.9 BioMerieux SA
  • 8.2.10 DiaSorin S.p.A
  • 8.2.11 Meridian BioscienceInc
  • 8.2.12 Quidel Corporation
  • 8.2.13 Thermo Fisher Scientific Inc
  • 8.2.14 Qiagen